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Abstract: A panel of docking scaffolds was developed for the known molecular targets of the
anticancer agents, thieno[2,3-b]pyridines, in order to glean insight into their mechanism of action.
The reported targets are the copper-trafficking antioxidant 1 protein, tyrosyl DNA phosphodiesterase
1, the colchicine binding site in tubulin, adenosine A2A receptor, and, finally, phospholipase C-δ1.
According to the panel, the A2A receptor showed the strongest binding, inferring it to be the most
plausible target, closely followed by tubulin. To investigate whether the thieno[2,3-b]pyridines
modulate G protein-coupled receptors (GPCRs) other than A2A, a screen against 168 GPCRs was
conducted. According to the results, ligand 1 modulates five receptors in the low µM region, four as
an antagonist; CRL-RAMP3 (IC50—11.9 µM), NPSR1B (IC50—1.0 µM), PRLHR (IC50—9.3 µM),
and CXCR4 (IC50—6.9 µM). Finally, one agonist, GPRR35, was found (EC50 of 7.5 µM). Molecular
modelling showed good binding to all of the receptors investigated; however, none of these surpass
the A2A receptor. Furthermore, the newly-identified receptors are relatively modestly expressed in
the cancer cell lines most affected by the thieno[2,3-b]pyridines, making them less likely to be the
main targets of the mechanism of action for this compound class. Nevertheless, new modulators
against GPCRs are of an interest as potential hits for further drug development.
Keywords: docking; molecular and homology modelling; drug discovery; chemical space
1. Introduction
Reynisson et al. [1] have established that the class of thieno[2,3-b]pyridines (TPs) have potent
anticancer activity against a variety of tumour cell lines. Their activity was discovered by the virtual
high throughput screen (vHTS) against the phospholipase C-γ2 (PLC-γ2) isoform, a potential molecular
target for anticancer therapy [2]. Testing against the National Cancer Institute’s human tumour cell
line panel (NCI-60) [3] revealed that the most potent analogues had low nano-molar growth inhibition,
particularly against breast and melanoma tumour cell lines, but also against other cancer types [4–7].
TPs are reported to modulate a number of molecular targets that are implicated in cancer
progression: (i) phospholipase C-δ1/3 (PLC), deduced by the same cellular behaviour of the
MDA-MB-231 breast cancer cell line upon administration of TP and the knockout (silencing) of
the PLC-δ1/3 genes; [8,9] (ii) copper-trafficking antioxidant 1 (ATOX1) protein, the inhibition of
which reduces the proliferation of cancer cells [10]; (iii) tyrosyl DNA phosphodiesterase 1 (TDP 1),
a phospholipase D enzyme, involved in repairing DNA damage [11]; (iv) the colchicine binding
site in tubulin [12,13], an established target for anticancer drugs; and (v) adenosine A2A receptor
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(A2AAR) [14], a G protein-coupled receptor (GPCR) implicated in the immune response to tumours [15].
The reported targets are shown in Figure 1, along with the most potent measured inhibition value and
the corresponding TP molecular structure.
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finally, 6 is the most active analogue for A2AAR. Since these derivatives were discovered by different 
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should have a unique structure-activity relationship, resulting in different TP derivatives being tested. 
When this is considered in terms of chemical space, Figure 2 can be produced to map locations of the 
active derivatives, in which each ellipse represents the active volume of chemical space for each target. 
Taking into account the available data, an extensive overlap between the aforementioned targets can 
be envisioned. It is currently not known which receptor/enzyme’s modulation produces the 
pronounced anticancer potential of the TPs or indeed whether a synergistic effect is responsible for 
the efficacy. For the further development of the TPs as potential clinical candidates, it is vital to 
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Figure 2. The possible location of the potent TP derivatives in chemical space relevant to the volumes 
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targets. Also, various deriv tives of the T s give t e best response, i.e., 1 nd 2 give excellent overall
potency in cell-based assays pointing to PLC-δ inhibition, 3 gives the most favourable IC50 for TDP1,
4 has the best tubulin inhibition profile, whereas 5 has the lowest reported Kd against ATOX1, and,
finally, 6 is the most active analogue for A2AAR. Since these derivatives were discovered by different
research groups, not using the same compound collections and synthetic strategies, it is not surprising
that various derivatives of TP were discovered and developed. Furthermore, each molecular target
should have a unique structure-activity relationship, resulting in different TP derivatives being tested.
When this is considered in terms of chemical space, Figure 2 can be produced to map locations of the
active deri at ves, in which each ellipse represents t e a tive volume of chemical space for ach target.
Taking int account the available data, an extensive overlap b tween the aforementioned targ ts can be
envisioned. It is currently not known which receptor/enzyme’s modulation produces the pronounced
anticancer potential of the TPs or indeed whether a synergistic effect is responsible for the efficacy.
For the further development of the TPs as potential clinical candidates, it is vital to elucidate the
molecular mechanism responsible for its potency.
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The predicted binding affinities should give an indication as to which experiments are most likely to
shed light on the mode of action of this class of anticancer compounds.
2. Results
A docking panel of the putative bio-molecular targets of the TPs was developed consisting of
PLC-δ1, ATOX1, TDP1, tubulin’s three binding sites, and the A2AAR GPCR. The aim was to compare
the scores of the docked TPs derivatives in order to establish which target is most likely to be modulated,
thus leading to the observed anticancer effects.
2.1. PLC-δ1
There is evidence for PLC-δ1 supporting the growth and migration of neoplastic mammary
epithelial cells, linking this target to cancer growth [16]. Upon docking to PLC-δ1, derivatives 1–6
were predicted to have the same/similar binding modes previously reported using both GOLD and
Glide [1,4,5,11]. Similar poses were generated with consistent interactions and strong affinity, as well
as good overlap with the co-crystallised inositol 1,4,5-triphosphate. Hydrogen bonds with Asn312,
Lys438, and His311 were observed as well as the side chains of Glu341, Tyr551, and Gly554, as shown
in Figure 3.
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The ATOX1 copper trafficking protein is linked to reduced proliferation of cancer cells 
demonstrated by knockout experiments of its gene [10]. Compound 6 is reported to form hydrogen 
bonds with the side chains of Glu17, Arg21, and Lys 60 amino acid residues, blocking the protein-
protein interface of ATOX1 for copper ion delivery [10]. In the case for 1 and 2 using GOLD, similar 
poses were predicted as those reported. Compound 1 blocked the copper-trafficking interface by 
forming a hydrogen bond with Arg21 and lipophilic contacts with Ala18 and Lys60, as shown in 
Figure 4, whilst 2 displayed hydrogen bonding interactions with Cys15 and Thr58, as well as a 
lipophilic contact between the phenyl and Lys60. Glide predicted a binding mode for 6 in which its 
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amide NH moiety. Cys12 and Cys15 are two of the four cysteine residues, which coordinate with a 
copper ion at the interface of two protein chains of ATOX1, thus blocking access to these residues 
inhibiting ion transfer. In the case of 1, however, a different binding pose was observed with the 
phenyl ring close to Lys60 and formed a hydrogen bond with Arg21.  
Figure 3. The docked conf rmation of 1 in the bi site of PLC-δ1 using ChemPLP. (A) Hydrogen
bonds (HB) are depicted as green dotted lines bet ee ligand and the amino acids Asn312, Lys438,
Glu341, Arg549, His311, and pi-pi stacking, with Tyr551 shown with dashed purple lines; (B) 1 shown in
the binding pocket with the protein surface rendered. Purple represents hydrogen bond donor regions
and green depicts hydrogen bond acceptor regions.
2.2. ATOX1
The ATOX1 copper trafficking protein is linked to reduced prolif ra ion of cancer cells
demonstrated by knockout experiments of its gene [10]. Compound 6 is reported to form hydrogen
bonds with the side chains of Glu17, Arg21, and Lys 60 amino acid residues, blocki g the protein-protein
interface of ATOX1 for copper ion delivery [10]. In the case for 1 and 2 using GOLD, similar poses
were predicted as those reported. Compound 1 blocked the copper-trafficking interface by forming a
hydrogen bond with Arg21 and lipophilic contacts with Ala18 and Lys60, as shown in Figure 4, whilst 2
displayed hydrogen bonding interactions with Cys15 and Thr58, as well as a lipophilic contact between
the phenyl and Lys60. Glide predicted a binding mode for 6 in which its thieno[2,3-b]pyridine moiety
is positioned between Glu17, Arg21, and Lys60 side chains, with a hydrogen bond with the Glu17
side chain via its amino group and with the Cys12 side chain with the amide NH moiety. Cys12 and
Cys15 are two of the four cysteine residues, which coordinate w th a co p r ion at the interface of two
protein chains of ATOX1, thus blocking access to these residues inhibiting ion transfer. In the case of
1, however, a different binding pose was observed with the phenyl ring close to Lys60 and formed a
hydrogen bond with Arg21.
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Figure 4. The docked conformation of 1 to the binding site of ATOX1 using GS. (A) Hydrogen bonds
(HB) are depicted as green dotted lines between 1 and the amino acid Arg21. Furthermore, a lipophilic
contact (LC) is shown as purple dashed lines between Lys60 and derivative 1; (B) 1 shown in the
binding pocket with the protein surface rendered. Purple represents hydrogen bond donor regions and
green depicts hydrogen bond acceptor regions.
2.3. TDP1
Camptothecin and its analogues (e.g., topotecan and irinotecan) constitute an effective and widely
used class of cancer therapeutics. They work by inhibiting the enzyme DNA topoisomerase I (topo I),
preventing DNA replication. In human cells, TDP1 is important to the mechanism for removing
DNA lesions [17,18]. In cancer cells, however, TDP1 counters the action of camptothecin by repairing
drug-created stalled topo I-DNA complexes, thus making TDP1 a potential anticancer target [19,20].
For T , both His263 nd His493 are proposed to lay a key role in its biological function and, as such,
the binding pocket is defined at th se amino acids [21–23]. When docke o TDP1 using GOLD, all the
ligands fitte into the p cket in a similar way as those depicted for 1 in Figure 5. These results are in
line with previously published modelling data for the TPs [11]. Glide predicted a good fit for all the
ligands, despite some variations in hydrogen bonding patterns, as for the GOLD predictions. The main
difference between the Glide- and GOLD-predicted poses was the reverse orientations of the phenyl
and thieno[2,3-b]pyridine rings.
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2.4. Tubulin
Tubulin-targeting agents are widely used for the treatment of cancer. They disrupt/inhibit tubulin
dynamics by acting as stabilisers or destabilisers. Three different binding sites have been identified for
targeting microtubules, namely colchicine-, taxol-, and Vinca alkaloid-binding pockets [24].
In order to establish the most plausible binding pocket for the TPs, 1–6 were docked to the three
identified sites and the results are given in Table 1. A clear trend is seen for the colchicine site predicted
for the GS and Glide values, with the ChemPLP results also leaning towards this site. CS and ASP
gave similar scores for all three sites. Furthermore, the results are in line with earlier findings where
TP derivatives have been predicted to bind to the colchicine site [12,13].
Table 1. The predicted scores of the TPs with tubulin’s colchicine-, taxol-, and Vinca alkaloid binding sites.
Colchicine Taxol Vinca
No GS CS PLP ASP Glide GS CS PLP ASP GS CS PLP ASP Glide
1 63.9 31.4 54.9 25.4 −6.7 52.9 30.9 52.6 26.3 59.1 30.6 57.2 30.1 −3.8
2 62.5 29.6 61.3 28.0 −6.9 50.8 29.7 50.9 25.5 55.9 29.4 49.3 28.7 −3.1
3 63.2 25.9 53.4 27.8 −5.7 57.2 31.5 59.1 29.9 54.3 26.4 52.3 31.8 −4.2
4 64.4 28.9 68.1 24.8 −7.4 50.5 29.8 53.2 23.7 49.9 25.2 53.1 27.3 −2.8
5 65.7 32.7 63.4 31.9 −5.8 51.8 28.8 51.9 24.8 52.2 27.2 54.4 28.9 −4.1
6 62.3 26.4 52.7 28.7 −7.4 51.6 28.0 54.0 26.2 55.1 27.9 52.7 28.2 −4.3
According to the GOLD docking results, compounds 1–6 have a similar predicted configuration
in the colchicine-binding site and showed stacking/polar interactions with tubulin (Figure 6), sitting
deep in the hydrophobic pocket (Ser178, lipophilic contacts with Ala180 and Val181). Docking results
with Glide were highly consistent for TPs 1–6, yet somewhat different from those produced by GOLD.
The binding affinities of the Glide predictions were high, and a common hydrogen bond with Val181
backbone NH, also a feature of co-crystallised colchicine, was observed.
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five potential antagonist receptors and one agnostic receptor. In brief, ligands where considered as 
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2.5. Testing for GPCRs Activity
One of the reported targets for the TPs is the A2AAR GPCR receptor with nano-molar activity [14].
It is estimated that 30–50% of all drugs on the market target GPCR receptors [25]. It was therefore
decided to investigate whether the TPs modulate other GPCR receptors.
Derivative 1 was screened against the gpcrMAX Panel containing 168 receptors in both agonist
and antagonist formats at 10 µM by the DiscoverX company [26]. The analysis of the data revealed five
potential antagonist receptors and one agnostic receptor. In brief, ligands where considered as potential
antagonists with inhibition >35% and agonists with activity >30% (see Tables S8–S10 in Supplementary
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Materials). These six receptors were tested for dose-response to quantify their effect and five targets
(four antagonists/one agonist) were active; the results are shown in Table 2. The receptor, HTR1B,
showed activity in the primary screen but had IC50 > 50 µM for the dose-response and was therefore
not considered to be a hit. The dose response curves are given in the Supplementary Information
pages 15 and 16. Furthermore, the complete technical reports from the company DiscoverX containing
controls are available in the Supplementary Information.
The five receptors are modulated by TP 1 in the low µ-molar region and are therefore less potent
than A2AAR (ADORA2A), the known GPCR, which was unfortunately not in the screening panel.
Interestingly, a related Adenosine A3 (ADORA3) receptor was in the panel and some activity was
observed (25%) in the antagonist format, but not enough to be taken forward for quantitative testing.
Recently, a panel of TPs was tested for in vitro anti-platelet activity and showed both platelet activation
and aggregation [27]. The authors concluded that the TPs are potential inhibitors for the P2Y12 receptor,
the target for clopidogrel, the standard clinical therapeutic. The P2Y12 receptor (P2RY12) had 13%
agonistic activity according to the assay, but no antagonist modulation was observed.
The activity of 1 against the identified targets was relatively modest, in the low µ-molar range (see
Table 2), which implies that the low nano-molar activity seen against some tumour cell lines cannot be
explained by the modulation of these receptors. Nevertheless, identifying activity against any GPCRs
is helpful in elucidating their mechanisms of action and in the development of potent small molecules
against specific receptors.
Table 2. Quantitative modulating values of compound 1 against the identified G protein-coupled
receptors (GPCRs). Antagonists values are given as Inhibition Concentration of 50% (IC50) and agonist
as half maximal effect concentration (EC50).
GPCR µM
CRL-RAMP3 IC50 11.9
NPSR1B IC50 1.0
PRLHR IC50 9.3
CXCR4 IC50 6.9
GPR35 EC50 7.5
Molecular modelling was performed in order to analyse and compare the binding mode of the
TPs against A2AAR and the identified receptors. A2AAR and CXCR4 both have published crystal
structures [28,29], and CRL-RAMP and GPR35 have published homologies models [30,31]. Protein
structures for NPSR1B and PRLHP were obtained from the GPCR database [32].
2.5.1. A2AAR
The A2AAR receptor is linked to the immune response of tumours by T regulatory cell function,
suppression and modulation of natural killer cell cytotoxicity, and tumour-specific CD4+/CD8+
activity [15]. In the case of A2AAR antagonists, a common binding motif involves pi-pi stacking between
aromatic moieties of the ligands and the Phe168 side chain, as well as hydrogen bonding interactions
with Asn253 and Glu169 side chains [14].
GOLD and Glide predicted very similar binding poses for compounds 1–6. Key interactions such
as hydrogen bonding with Asn253 and Glu169 side chains and pi-pi stacking with the Phe168 aromatic
side chain were common among the derivatives, as were high binding affinities (Figure 7).
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Figure 7. The docked conformation of 1 to the binding site of A2AAR using ChemPLP. (A) Hydrogen
bonds (HB) are depicted as green dotted lines between ligand and the amino acids Asn253 and Glu169.
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2.5.2. CXCR4
CXCR4 is a chemokine receptor involved in cancer metastasis and inflammatory diseases, as well
as HIV-1 infection [29]. Interestingly, modulation of this receptor with small organic ligands has been
reported for both metastasis and inflammation [33].
GOLD predicted hydrogen bonding between Try94 and Asp97 side chains via the amino
group of the TPs as seen for 1 in Figure 8. Also, pi-pi stacking with Trp94 side chain was observed
for some compounds with the thieno[2,3-b]pyridine ring. Glide docking was very consistent
in terms of binding poses, which were in agreement with the GOLD predictions and the co-
crystallised conformation of ITD ((6,6-dimethyl-5,6-dihydroimidazo [2,1-b] [1,3]thiazol-3-yl)methyl
N,N′-dicyclohexylimidothiocarbamate).
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2.5.3. CRL-RAMP3
Calcitonin receptor-like activity modifying protein 3 (CRL-RAMP3), is a member of the RAMP
family of receptors, single transmembrane-domain proteins. CRL-RAMP3 regulates calcitonin and is a
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linear polypeptide hormone involved in the calcium ion regulation in blood [34]. The CRL-RAMP3
complex has been indicated to be important to angiogenesis and therefore to tumour growth [35].
A published homology model of RAMP3 was used for the modelling [30]. The model of RAMP3
suggests that Tyr84 can contact the Try52 of adrenomedullin (AM) and calcitonin gene-related peptides
(CGRP) Phe37 phenyl rings and is therefore expected to decrease the potency of both peptides at
the AM2 receptor [36,37]. Furthermore, Glu74 and Tyr84 may interact with ligands that bind to the
CRL-RAMP3 heterodimer.
The GOLD and Glide docking predicted similar poses for all ligands, which occupied the cleft
between CRL and RAMP3. They were observed to pi-pi stack with Trp72 and Tyr124 aromatic side
chains of CRL. The thieno[2,3-b]pyridine moiety was surrounded by RAMP3 residues Glu74, Trp84,
and Arg38 (Figure 9).
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Fig re 9. The docked confor ation of 1 to the binding site of LR-R P3 using ChemPLP. ( )
r en bond (HB) is depicted as green dotted line between ligand and the amino acid Arg38.
Tyr52 and Trp84 are in lipophilic contact (LC) with the ligand shown with dashed purple lines; (B) 1 is
s i t e i i g cket ith t e r tein s rface re ered a see s to fit i t l ft t
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2.5.4. GPR35
G protein-coupled receptor 35 (GPR35) is important to the tryptophan metabolic pathway, acting
as the receptor for the intermediate kynurenic acid. The homology odel of human GPR35 (hGPR35)
with bufrolin docked in the active site was provided by McKenzie et al. [31]. Re-docking of bufrolin
resulted in relatively low RMSD values with an average of 2.3 Å, indicating good reproducibility.
Docking of the TPs using GOLD yielded plausible binding poses. Hydrogen bonds were predicted
with Arg239 side chain amide NH2 via the carbonyl on cycloalkane and with Arg148 via NH2 on the
thiophene ring. The TPs are predicted to form pi-pi stacking with Phe147.
Glide docking predicted two different binding trends for 1–6. Compounds 1 (Figure 10), 3, and 6
aligned in a similar way as was observed with GOLD, forming hydrogen bonds with Asn230 and
Arg239 side chains. Alternatively, 2, 4, and 5 formed two hydrogen bonds; one with the Cys146
backbone and one with the Ser246 side chain.
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Figure 10. The docked configuration of 1 to the binding site of GPR35 using PLP scoring function.
(A) Hydrogen bonds (HB) are depicted as green lines between the ligand and the amino acid Tyr243
and Arg239. The pi-pi stacking is observed with Phe147 shown with a purple dashed line as well as
lipophilic contact (LC) with Val61, Phe145, and Leu242; (B) the protein surface is rendered. The bicyclic
group is inserted in a lipophilic pocket. Purple represents hydrogen bond donor regions and green
depicts hydrogen bond acceptor regions.
2.5.5. PSRb1
europeptide S receptor b1 (NPSRb1) is linked to bronchial smooth muscles and asthma
as well as inflammatory bowel disease [38]. Two residues in the second transmembrane region
(TM2) of human NPSRb1, namely Asn107 and Asp105, are reported to be important for antagonist
affinity [39,40]. Furthermore, three known antagonists of NPSRb1, with nano-molar activities, are
known (Figure 11) [41,42]. This information was used to locate the binding site of the receptor and to
assess which of the amino acid residues are important for a successful binding.
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Docking the kno n antagonists in the vicinity of the target residues yielded plausible binding
poses. The TPs al ost perfectly overlapped ith the predicted poses of kno n antagonists, S A66
and S A68. The phenyl ring as inserted into the cleft bet een t o T do ains and parallel to
helices, just like the p-fluorophenyl oiety of S A68 and the TP oiety as in contact ith the
extracellular do ain residues (Figure 12). In this confor ation, the carbonyl group for ed hydrogen
bonds with the a ino group of Ile106.
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Figure 13. The docked configuration of 1 to the binding site of PRLHR using GS scoring function.
(A) A hydrogen bond (HB) is depicted as green lines between the ligand and the amino acid Asn298.
The pi-pi stacking is observed with His321 and Trp291 shown as purple dashed lines; (B) 1 shown in the
binding pocket with the protein surface rendered. Purple represents hydrogen bond donor regions,
and green depicts hydrogen bond acceptor regions.
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3. Discussion
As 1–6 were docked using five different scoring functions, an estimate was generated to identify
which molecular targets are most likely to be modulated by the TPs. The scoring function results
are given for each derivative 1–6 in the Supplementary Information. The results, for the six ligands,
were averaged and the standard deviation was derived (Table 3).
Table 3. Predicted average scores and standard deviations for derivatives 1–6 against the identified
targets. The best scores are in bold and the second best in italics.
Targets GS CS PLP ASP Glide Total 1
1 PLC-δ1 56.9 ± 4.3 28.6 ± 1.8 63.1 ± 2.7 35.1 ± 1.3 −3.7 ± 0.8 7.7 ± 0.6
2 ATOX1 41.5 ± 1.8 19.9 ± 1.6 41.2 ± 3.7 16.1 ± 1.7 −2.2 ± 0.3 4.8 ± 0.4
3 TDP1 49.7 ± 0.9 26.8 ± 1.2 48.5 ± 3.7 31.2 ± 1.5 −3.2 ± 0.9 6.6 ± 0.5
4 Tubulin-Colchicine 63.7 ± 1.3 29.2 ± 2.7 58.9 ± 6.3 27.8 ± 2.5 −6.7 ± 0.7 8.1 ± 0.6
5 A2AAR 64.2 ± 2.8 38.6 ± 3.0 69.2 ± 1.9 40.4 ± 1.5 −8.8 ± 0.4 10.0 ± 0.5
6 CXCR4 62.6 ± 4.3 32.9 ± 1.3 66.4 ± 1.4 37.4 ± 3.0 −6.3 ± 0.3 8.9 ± 0.5
7 CRL-RAMP3 57.1 ± 1.5 31.7 ± 1.9 64.1 ± 4.3 36.7 ± 2.1 −5.7 ± 0.1 8.4 ± 0.4
8 GPR35 62.9 ± 1.9 32.2 ± 1.7 62.6 ± 3.9 38.4 ± 1.7 −4.7 ± 0.6 8.4 ± 0.5
9 NSPRb1 49.9 ± 2.1 27.1 ± 1.9 58.1 ± 4.6 31.1 ± 1.5 −4.3 ± 0.5 7.2 ± 0.5
10 PRLHR 56.7 ± 2.9 32.8 ± 3.1 56.9 ± 3.8 32.9 ± 1.4 −5.5 ± 0.8 8.0 ± 0.5
1 Scores normalised to A2A (=10) and corresponding standard deviations.
Looking at the results, for GS A2AAR has the highest score, closely followed by tubulin,
CXCR4, and GPR35, while the other targets have clearly lower predicted scores. CS again predicts
A2AAR to have the highest score, with the second highest shared by the rest of the GPCRs, except
NSPRb1. The ChemPLP scoring function put A2AAR as the top target, followed by CXCR4 and
CRL-RAMP3. ChemPLP has been shown to be the best, or one of the best, performing scoring functions
available [44,45]. ASP predicted A2AAR to be the best, followed by CXCR4 and GPR35. Finally,
Glide predicted A2AAR to have the highest affinity with the TPs, followed by tubulin. Based on these
results, it is apparent that A2AAR is the most likely target, with the highest predicted score for all of
the scoring functions used.
The results for all the scoring functions were normalised to the highest score (A2AAR), giving
them an equal weight. They were then summed and divided to give the best score of 10 (Total column
in Table 3) and standard deviations were derived. When these numbers were analysed, it was seen
that the GPCRs were predicted to be modulated, except NSPRb1, with tubulin also obtaining a good
score, followed by PLC-δ1. According to this analysis, the TPs mostly exert their anticancer effect by
GPCR modulation.
As can be seen in Figure 1, the TPs derivatives do not have radically different chemical structures;
however, when the scoring data is analysed, notable shifts in predicted affinities are observed, e.g.,
removing the substituents on the phenyl ring from 1 resulting in 2 increases the affinity of the latter
towards PLC-δ1 for both the GS and PLP scoring functions (see Tables S2–S7 in the Supplementary
Materials). This means that each modification of the TPs changes the affinity to many of the targets,
rendering it very difficult to generate a reliable structure activity relationship (SAR) for cell-based
data. Thus, it is a multidimensional problem to optimise the TPs’ structure for anticancer activity.
The changes in water solubility and, consequently, cell penetration, between the derivatives also needs
to be considered, adding further complexity to the problem.
Transcript Levels in the Cancer Cells Affected by TPs
The NCI60 transcriptome database and Cellminer tools [46] (discover.nci.nih.gov/cellminer) were
used to assess the expression of mRNA of the identified targets in the National Institute of Cancer
human tumour cell lines panel (NCI-60) [3]. The z-score representations, a measure of mRNA transcript
intensity [46], were collected for all the available targets and the results are given in the Supplementary
Materials. Unfortunately, CRL-RAMP3 and PRLHR were not available in the database. The melanoma
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cell line MDA-MB-435 is the most susceptible tumour cell for the TPs in the NCI-60 panel and the
z-scores for the targets are given in Table 4, as well as the minimum and maximum values given for
the cell line panel.
Table 4. The expression levels (z-scores) of the targets in the melanoma MDA-MB-435 cell line. Also,
the minimum and maximum values are given.
Target z-Score Min. Max.
PLC-δ1 0.129 −1.088 −4.413
ATOX1 1.055 −0.905 2.886
TDP1 −0.184 −4.662 1.716
Tubulin −0.822 −0.880 2.877
A2AAR −0.777 −1.412 2.622
CXCR4 −0.667 −0.687 3.615
GPR35 −0.483 −0.514 4.056
NSPRb1 −0.284 −0.503 6.804
According to the values in Table 4, only PLC-δ1 and ATOX1 have positive values, i.e., significant
mRNA is expressed in this cell line making these targets plausible. TDP1 is expressed to some level
but TDP1’s expression levels are expected to rise under stress, leading to DNA damage (such a
chemotherapy) to aid the cell to survive. Also, tubulin is heavily expressed during mitosis, making it
abundant during cell duplication in all of the cancer cell lines. In general, the transcript intensity of the
GPCR receptors is low, in particular for CXCR4, but GPR35, A2AAR, and NSPRb1 are expressed to
some extent.
For further analysis, the expression levels of each target were considered and correlated with the
GI50 values of ligand 1, as shown in Tables S11–S20 in the Supplementary Materials.
In general, the data suggest that gene expression level is necessary, but not sufficient, to predict
the efficacy of inhibition. mRNA abundance and consequent protein expression are known to correlate
poorly due to complex biological and technical issues [47].
4. Materials and Methods
4.1. Molecular Modelling
Using GOLD [48] and Glide [49] software suites, the compounds were docked to the crystal
structure of PLC-δ1 (PDB ID: 1DJX, resolution 2.3 Å) [50], ATOX1 (PDB ID: 1FEE, resolution 1.8 Å) [51],
TDP1 (PDB ID: 1MU7, resolution 2.0 Å) [21], A2AAR (PDB ID: 3EML, resolution 2.6 Å) [28], and CXCR4
(PDB ID: 3ODU, resolution 2.5 Å) [29], which were obtained from Protein Data Bank (PDB) [52,53].
To rationalise the mechanistic action of the TPs to tubulin, they were docked to the tubulin crystal
structures of the three main binding sites: colchicine, Vinca alkaloid, and taxol with the respective
PDB IDs of 4O2B (resolution 2.3 Å) [54], 4EB6 (resolution 3.47 Å) [55], and 1JFF (resolution 3.5 Å) [56].
The centres of the binding pockets were defined as the position of the position of the Ca2+ ion (x = 78.99,
y = 38.878, z = −19.069) for PLC-δ1, the sulfur of Cys12 (x = 66.121, y = −55.634, z = 36.866) for ATOX1,
the position of the tungsten (W) of the co-crystallised ligand (x = 8.312, y = 12.660, z = 34.452) for TDP1,
the co-crystallised ligand centre point (x = −9.420, y = −9.544, z = 56.644) for A2AAR, and the centroid
of the co-crystalised ligand (x = 20.266, y = −6.133, z = 72.241) for CXCR4. For tubulin, the centre of
co-crystallised colchicine (x = 13.222, y = 8.371, z = −23.331), taxol (x = 2.182, y = −15.848, z = 15.866),
and vinblastine (x = 13.391, y = 90.610, z = 103.739) were used.
For the docking studies using GOLD, 50 docking runs were allowed for each ligand with default
search efficiency (100%). The GoldScore (GS) [57], ChemScore (CS) [58,59] Piecewise Linear Potential
(ChemPLP) [60], and Astex Statistical Potential (ASP) [61] scoring functions were implemented to
predict binding modes and relative energies of ligand-receptor complexes. The Scigress ultra version
F.J 2.6 program [62] was used to prepare the crystal structures for docking, i.e., hydrogen atoms were
Molecules 2017, 22, 2254 13 of 17
added and crystallographic water molecules and co-crystallised ligands were removed. The basic
amino acids, lysine and arginine, were defined as protonated. Furthermore, aspartic and glutamic acids
were assumed to be deprotonated. The Scigress software suite was also used to build the inhibitors
and the MM2 [63] force field was used to optimise the structures.
For Glide, the crystal structures were prepared using Protein Preparation Wizard of Maestro [64],
where hydrogens were added, ionisation and tautomeric states were generated by Epik, and proton
orientations were set by PROPKA [64]. The same coordinates as those used for GOLD were used
for search the space centre in grid generation, and the van der Waals radii of non-polar receptor
atoms (partial charge cut-off 0.25) were scaled down to 0.8 Å. Ligands were docked at extra precision,
post-docking minimisation was enabled, Epikstate penalties were added to docking scores, and a
maximum of 10 poses were recorded per ligand.
In order to verify the robustness of the docking protocol, the available co-crystallised ligands were
re-docked and their RMSD (Root-Mean-Square Deviation) values generated. The results are shown in
Table S1 in the Supplementary Materials, and an adequate to excellent overlap was obtained.
4.2. Homology Modelling
The homology models were prepared with Protein Preparation Wizard of Maestro [64]. For the
models of NPRS1B and PRLHR, which were obtained from the GPCR data base [32], restrained force
field minimisation was performed with convergence of heavy atoms to an RMSD of 0.5 Å to prevent
clashes. The coordinates of N1 of Trp-72 (chain A) side chain for CALCRL-RAMP3, the centroid of
docked bufrolin for GPR35, the midpoint of Asp105 and Asn107 for NPSR1B, and the centroid of the
predicted cavity by Site Map (Schrödinger, LLC, New York, NY, USA, 2015) [64] for PRLHR were
picked as the centres of search spaces for each model.
4.3. Biological Testing
Compound 1 was screened against the gpcrMAX Panel using 168 different GPCR receptors, in
both agonist and antagonist formats. The assays were performed using the PathHunter beta-arrestin
enzyme fragment complementation (EFC) technology at DiscoverX [26]. The full data set and the
analysis protocol are given in the Supplementary Materials.
5. Conclusions
This work communicates the discovery of activity of TPs against GPCRs, albeit in the low µM
range. Finding potent ligands against unexplored GPCRs is very helpful in the elucidation of their
nature and is the first step in developing a specific ligand for modulation and possibly a clinical
candidate. The modelling data indicates A2AAR and tubulin to be the most likely targets of the TPs;
however, when protein expression data is considered, other targets such as ATOX1 and PLC-δ1 are
evidenced to play a role in the anticancer activity of this class of compounds. It is clear that the TPs
are prolific inhibitors/modulators of various targets and can therefore be categorised as a privileged
structure in drug discovery [65]. The challenge is to develop the TPs to be specific against the target of
interest in order to develop them into viable drug candidates.
Supplementary Materials: The following are available online at www.mdpi.com/1420-3049/22/12/2254/s1,
Table S1: RMSD values of co-crystallised ligands after docking, Table S2: predicted interaction of thienopyridines
(1) with bio-molecular targets and their binding energies, Table S3: predicted interaction of thienopyridines (2)
with bio-molecular targets and their binding energies, Table S4: predicted interaction of thienopyridines (3) with
bio-molecular targets and their binding energies, Table S5: predicted interaction of thienopyridines (4) with
bio-molecular targets and their binding energies, Table S6: predicted interaction of thienopyridines (5) with
bio-molecular targets and their binding energies, Table S7: predicted interaction of thienopyridines (6) with
bio-molecular targets and their binding energies, Table S8: assay mode: agonist, 10 µM of 1, Table S9: assay mode:
antagonist, 10 µM of 1, Table S10: results of the dose response experiments for the receptors, Table S11: average
transcript intensity z scores (ATOX1), Table S12: average transcript intensity z scores (PLC δ1), Table S13: average
transcript intensity z scores (PLC δ3), Table S14: average transcript intensity z scores (TDP1), Table S15: average
transcript intensity z scores (Tubulin Beta 2B), Table S16: average transcript intensity z scores (Tubulin Alpha 1A),
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Table S17: average transcript intensity z scores (A2AAR), Table S18: average transcript intensity z scores (CXCR4),
Table S19: average transcript intensity z scores (GPR35), Table S20: average transcript intensity z scores (NPSRB1).
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